| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ACADACADIA Pharmaceuticals Inc. | 4.48B | 26.46 | 19.46 | 31.85% | 24.94% | 28.47% | 3.51% | 0.07 |
| JAZZJazz Pharmaceuticals plc | 9.87B | 162.43 | 18.78 | 6.12% | -8.86% | -9.31% | 13.66% | 1.51 |
| CPRXCatalyst Pharmaceuticals, Inc. | 2.75B | 22.35 | 17.06 | 23.49% | 37.63% | 23.64% | 8.71% | 0.00 |
| HRMYHarmony Biosciences Holdings, Inc. | 2.06B | 35.76 | 14.25 | 22.8% | 22.48% | 22.23% | 10.62% | 0.28 |
| ALKSAlkermes plc | 4.81B | 29.15 | 13.43 | -6.36% | 22.27% | 19.55% | 8.43% | 0.05 |
| PRTCPureTech Health plc | 437.45M | 18.10 | 9.05 | 44.98% | -495.91% | -8.53% | 0.05 | |
| LBRXLB Pharmaceuticals Inc Common Stock | 500.67M | 19.79 | -1.11 | |||||
| NMRANeumora Therapeutics, Inc. Common Stock | 363.67M | 2.14 | -1.40 | -178.79% | 0.01 |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 50M | 0 |
| Revenue Growth % | - | - | - | -1% |
| Cost of Goods Sold | 0 | 329K | 0 | 258K |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | 0 | -329K | 50M | -258K |
| Gross Margin % | - | - | 1% | - |
| Gross Profit Growth % | - | - | 152.98% | -1.01% |
| Operating Expenses | 28.65M | 22.39M | 66.08M | 50.64M |
| OpEx % of Revenue | - | - | 1.32% | - |
| Selling, General & Admin | 6.29M | 5.5M | 6.32M | 12.47M |
| SG&A % of Revenue | - | - | 0.13% | - |
| Research & Development | 22.36M | 16.89M | 27.6M | 38.16M |
| R&D % of Revenue | - | - | 0.55% | - |
| Other Operating Expenses | -91K | 0 | 32.15M | 0 |
| Operating Income | -28.65M | -22.72M | -16.08M | -50.89M |
| Operating Margin % | - | - | -0.32% | - |
| Operating Income Growth % | - | 0.21% | 0.29% | -2.17% |
| EBITDA | -28.32M | -22.39M | -15.88M | -50.64M |
| EBITDA Margin % | - | - | -0.32% | - |
| EBITDA Growth % | - | 0.21% | 0.29% | -2.19% |
| D&A (Non-Cash Add-back) | 325K | 329K | 195K | 258K |
| EBIT | -28.67M | -23.86M | 23.38M | -42.26M |
| Net Interest Income | -255K | 373K | 4.4M | 8.9M |
| Interest Income | 77K | 761K | 4.61M | 8.9M |
| Interest Expense | 332K | 388K | 208K | 0 |
| Other Income/Expense | -354K | -1.53M | 39.25M | 8.64M |
| Pretax Income | -29M | -24.25M | 23.17M | -42.26M |
| Pretax Margin % | - | - | 0.46% | - |
| Income Tax | 0 | 0 | 450K | 0 |
| Effective Tax Rate % | 1% | 1% | 0.98% | 1% |
| Net Income | -29M | -24.25M | 22.72M | -42.26M |
| Net Margin % | - | - | 0.45% | - |
| Net Income Growth % | - | 0.16% | 1.94% | -2.86% |
| Net Income (Continuing) | -29M | -24.25M | 22.72M | -42.26M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.15 | -0.97 | 0.90 | -2.18 |
| EPS Growth % | - | 0.16% | 1.93% | -3.42% |
| EPS (Basic) | -1.15 | -0.97 | 0.90 | -2.18 |
| Diluted Shares Outstanding | 25.13M | 25.13M | 25.28M | 19.35M |
| Basic Shares Outstanding | 25.13M | 25.13M | 25.28M | 19.35M |
| Dividend Payout Ratio | - | - | - | - |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Total Current Assets | 69.78M | 48.39M | 127.71M | 206.39M |
| Cash & Short-Term Investments | 69M | 47.24M | 125.19M | 204.76M |
| Cash Only | 4.63M | 5.57M | 15.53M | 21.94M |
| Short-Term Investments | 64.37M | 41.67M | 109.66M | 182.82M |
| Accounts Receivable | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 0 | 0 | 2.52M | 1.63M |
| Total Non-Current Assets | 739K | 2.24M | 2.68M | 6.46M |
| Property, Plant & Equipment | 642K | 2.12M | 1.4M | 6.46M |
| Fixed Asset Turnover | - | - | 35.79x | - |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 97K | 129K | 1.28M | 3K |
| Total Assets | 70.52M | 50.64M | 130.39M | 212.85M |
| Asset Turnover | - | - | 0.38x | - |
| Asset Growth % | - | -0.28% | 1.57% | 0.63% |
| Total Current Liabilities | 3.67M | 7.55M | 5.48M | 9.97M |
| Accounts Payable | 660K | 430K | 635K | 1.81M |
| Days Payables Outstanding | - | 477.05 | - | 2.56K |
| Short-Term Debt | 1.25M | 3.95M | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 79K | 0 | 2.48M | 3.37M |
| Current Ratio | 18.99x | 6.41x | 23.29x | 20.69x |
| Quick Ratio | 18.99x | 6.41x | 23.29x | 20.69x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 5.26M | 3.82M | 192.84M | 4.81M |
| Long-Term Debt | 3.66M | 0 | 192.62M | 0 |
| Capital Lease Obligations | 0 | 791K | 108K | 4.81M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.6M | 3.02M | 110K | 0 |
| Total Liabilities | 8.93M | 11.37M | 198.32M | 14.78M |
| Total Debt | 4.91M | 5.85M | 193.19M | 6.26M |
| Net Debt | 279K | 280K | 177.67M | -15.68M |
| Debt / Equity | 0.08x | 0.15x | - | 0.03x |
| Debt / EBITDA | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - |
| Interest Coverage | -86.29x | -58.56x | -77.29x | - |
| Total Equity | 61.59M | 39.27M | -67.94M | 198.07M |
| Equity Growth % | - | -0.36% | -2.73% | 3.92% |
| Book Value per Share | 2.45 | 1.56 | -2.69 | 10.23 |
| Total Shareholders' Equity | 61.59M | 39.27M | -67.94M | 198.07M |
| Common Stock | 12K | 12K | 2K | 26K |
| Retained Earnings | -73.61M | -97.86M | -75.14M | -117.4M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | -35K | -76K | 108K | 71K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Cash from Operations | -26.27M | -20.12M | 19.35M | -32.84M |
| Operating CF Margin % | - | - | 0.39% | - |
| Operating CF Growth % | - | 0.23% | 1.96% | -2.7% |
| Net Income | -29M | -24.25M | 22.72M | -42.26M |
| Depreciation & Amortization | 325K | 329K | 195K | 258K |
| Stock-Based Compensation | 1.75M | 1.93M | 2.22M | 6.8M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 553K | 3.14M | -4.76M | -2.98M |
| Working Capital Changes | 108K | -1.27M | -1.02M | 5.33M |
| Change in Receivables | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | -110K | -230K | 0 | 1.14M |
| Cash from Investing | -64.97M | 22.3M | -65.57M | -69.74M |
| Capital Expenditures | -168K | -118K | -414K | -514K |
| CapEx % of Revenue | - | - | 0.01% | - |
| Acquisitions | - | - | - | - |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 |
| Cash from Financing | 79.84M | -1.24M | 56.18M | 109M |
| Debt Issued (Net) | - | - | - | - |
| Equity Issued (Net) | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - |
| Other Financing | 113K | 15K | -184K | 790K |
| Net Change in Cash | - | - | - | - |
| Free Cash Flow | -26.43M | -20.24M | 18.93M | -33.36M |
| FCF Margin % | - | - | 0.38% | - |
| FCF Growth % | - | 0.23% | 1.94% | -2.76% |
| FCF per Share | -1.05 | -0.81 | 0.75 | -1.72 |
| FCF Conversion (FCF/Net Income) | 0.91x | 0.83x | 0.85x | 0.78x |
| Interest Paid | 222K | 225K | 150K | 0 |
| Taxes Paid | 0 | 0 | 450K | 0 |
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Return on Equity (ROE) | -47.09% | -48.09% | - | -64.95% |
| Return on Invested Capital (ROIC) | - | -33.6% | -16.15% | -26.13% |
| Gross Margin | - | - | 100% | - |
| Net Margin | - | - | 45.44% | - |
| Debt / Equity | 0.08x | 0.15x | - | 0.03x |
| Interest Coverage | -86.29x | -58.56x | -77.29x | - |
| FCF Conversion | 0.91x | 0.83x | 0.85x | 0.78x |
| Revenue Growth | - | - | - | -100% |
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) saw revenue decline by 100.0% over the past year.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) reported a net loss of $59.4M for fiscal year 2024.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a return on equity (ROE) of -64.9%. Negative ROE indicates the company is unprofitable.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) had negative free cash flow of $52.8M in fiscal year 2024, likely due to heavy capital investments.